U.S. Markets closed

Starboard Is Against the Bristol-Myers and Celgene Deal. Now It Gets Interesting.

Al Root

Less than a month before shareholders vote on Bristol-Myers Squibb’s proposed take over of Celgene, activist hedge fund Starboard Value released a presentation detailing its opposition to the deal.